Ideas
Eric Rosengren
Former Boston Fed President, Visiting Scholar at MIT Gallup Center for Finance and Policy
9:14
Fed independence risk pressures long-end Treasuries.
If political pressure undermines Fed independence, markets may worry the Fed will tolerate higher inflation. Even if short-term rates fall, long-end Treasury yields would likely rise as inflation concerns build, pressuring long-duration Treasury prices.
Stephen Philipson
Vice Chair and Head of Wealth, Corporate, Commercial and Institutional Banking, U.S. Bancorp
11:37
BTIG fills equity capital markets gap.
U.S. Bancorp is acquiring BTIG for up to $1B to fill its equity product gap. The deal adds equity sales and trading, equity capital markets, M&A advisory, equity derivatives, and prime brokerage, allowing USB to capture fees it previously referred to BTIG. Management sees capital markets pipelines healthy and M&A-driven financing and hedging continuing, supporting fee income growth.
BNY posts records, raises profitability targets.
BNY Mellon reported record 2025 revenue, net income, and EPS, and raised medium-term ROTCE and pre-tax margin targets to 28% and 38%. Management sees 2-3 Fed cuts this year, over 5% NII growth, stable deposits, and is bullish on the economy and markets, with digital-asset and AI adoption supporting the franchise.
Teva pivots to biopharma pipeline growth.
Teva is transforming from a pure generics company to a biopharma company; branded/innovation sales should outpace generics by 2030 and the late-stage pipeline could generate nearly $12B by 2035. Existing innovative products are growing over 30%, multiple 2026 data readouts and launches are coming, and the long-acting olanzapine schizophrenia franchise could launch around late Q3/early Q4.
Capital markets supercycle favors big banks.
Capital markets are healthy and likely entering a supercycle, with continued M&A, financing, hedging, and a host of IPOs driving issuance. JPMorgan is a large holding and preeminent franchise, Bank of America is owned and levered to the upswing, and Goldman Sachs is also among the most levered beneficiaries.
Productivity boom supports stocks without rate cuts.
The stock market remains modestly constructive for investors, not because of rate cuts but because of a potential productivity boom. Strong productivity data could let GDP continue to do well even without Fed easing, though high ~22x forward P/E makes delivery harder.
AstraZeneca pipeline supports ambitious sales target.
AstraZeneca's $80B 2030 sales target looks increasingly achievable after 16 positive Phase 3 readouts in 2025 and another 20 Phase 3 trials expected in 2026. M&A will stay disciplined around core therapeutic areas, and its oral GLP-1 plus selective amylin and GLP-1/glucagon assets position it in a large and expanding obesity market.
Oral obesity pill drives Novo growth.
Novo Nordisk's oral obesity pill launch addresses a large group that wanted GLP-1 weight loss but avoided injections. The pill has 16.6% efficacy equal to the Wegovy pen, CV benefits competitors lack, and management can produce enough profitably; pricing deals with Medicare and Medicaid broaden access.
China reopening boosts Illumina growth outlook.
Illumina ended 2025 with 7% ex-China Q4 growth and 15% full-year EPS growth despite sanctions, NIH funding pressure, and tariffs. China's ban on selling sequencers was removed and management sees a big growth opportunity once remaining unreliable-entity-list issues are resolved; NIH grant clarity should help academic customers over coming quarters.
This Bloomberg Markets video, published January 13, 2026,
features Eric Rosengren, Stephen Philipson, Dermot McDonogh, Richard Francis, Macrae Sykes, Jonathan Levin, Ariana Sarin, Mike Doustdar, Jacob Thaysen
discussing US long-end Treasuries, USB, BK, TEVA, JPM, BAC, GS, SPY, AZN, NVO, ILMN.
9 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Eric Rosengren,
Stephen Philipson,
Dermot McDonogh,
Richard Francis,
Macrae Sykes,
Jonathan Levin,
Ariana Sarin,
Mike Doustdar,
Jacob Thaysen
· Tickers:
US long-end Treasuries,
USB,
BK,
TEVA,
JPM,
BAC,
GS,
SPY,
AZN,
NVO,
ILMN
